vom 10/19/2016

Symposium “55th Heidelberg Grand Round” with international Cancer experts

The National Center for Tumor Diseases (NCT) Heidelberg is holding a high-level forum of experts under the heading “Big Shots against Cancer” on Tuesday, 25 October 2016 from 4 pm. For the 55th time, the “Grand Heidelberg Round” is meeting with world-renowned cancer experts. The basic researchers and clinicians Alexander Eggermont, Jordi Rodon, Michael Sadelain and John Mendelsohn will report about milestones and challenges in cancer research. The lectures will be held in the auditorium of the German Cancer Research Center (DKFZ). The NCT Heidelberg is a joint institution of the German Cancer Research Center (DKFZ), University Hospital Heidelberg and German Cancer Aid (Deutsche Krebshilfe).

What are the great achievements in cancer research to date? What are the changes to be expected in the current therapies over the next years? International cancer researchers will be dealing with these questions on October 25 during the 55th “Heidelberg Grand Round” (HGR) in their lectures:

Professor Alexander Eggermont, Head of the Gustave Roussy Cancer Research Institute in Paris investigates how cancer cells manage to thwart the immune system, and how scientists can resolve this.
Patients suffering from a rare type of cancer are faced with a multitude of additional problems:There is often a considerable time lag between diagnosis and therapy, as even experts may be unsure as to which treatment is best. Professor Jordi Rodon from the Vall Hebron Institute of Oncology (VHIO) in Barcelona reports how clinical studies can be performed for these small patient groups, to improve the situation of people with rare diseases.

Professor Michel Sadelain from the Memorial Sloan Kettering Cancer Center in New York conducts research into genetically modifying immune system cells so that they attack the tumor. He will report in his talk how far they have come.

A personal journey through 36 years of research in precision oncology will be presented by Professor John Mendelsohn, a pioneer in the field of personalized cancer therapy. The Past President of the MD Anderson Cancer Center of Texas University is currently Director of the Khalifa Institute for Personalized Cancer Therapy, also in Houston.

Eggermont und Mendelsohn support and advise the NCT Heidelberg as members of the Scientific Advisory Board.

The two-hour training event will take place in the large auditorium at DKFZ on October 25, from 4 pm. The meeting will be chaired by Professors Christof von Kalle and Dirk Jäger, both Directors at the NCT, as well as Peter Krammer from the DKFZ. “We started the “Heidelberg Grand Round” in 2005 in order to bring basic researchers and physicians closer together. This regular meeting gives scientists an opportunity to exchange views and knowledge across various disciplines” says Peter Krammer, founder of the event series. The meetings are held 5 times a year covering various topics in translational oncology.

The meeting is recognized as a training event for physicians and scientists by the Medical Association Baden-Württemberg (Landesärztekammer). The registration deadline is October 24.
Register online at www.nct-heidelberg.de/anmeldung or by email: hso@nct-heidelberg.de

“As this is the 55th anniversary of the HGR, we want to commemorate this special jubilee. Following the scientific part of the symposium, we would like to invite all the participants to take part in a small celebration”, adds von Kalle. In a casual atmosphere, participants are welcome to continue the exchange and enjoy some drinks, refreshments and live music.

Education and Event Office
Of the National Center for Tumor Diseases (NCT) Heidelberg
School of Oncology
Im Neuenheimer Feld 460
69120 Heidelberg
Phone: +49 6221 56-6558
Fax: +49 6221 56-5094

Deutsches Krebsforschungszentrum (DKFZ)
Kommunikationszentrum, Large Auditorium
Im Neuenheimer Feld 280
69120 Heidelberg

The program for the event is available at

Journalists are very welcome. Please let us know in advance if you will attend and who you would like to speak to. Your contact person is Dr. Friederike Fellenberg, NCT Press and Public Relations, Phone +49 (0)6221 56-5930, friederike.fellenberg@nct-heidelberg.de.

Dr. Friederike Fellenberg
Nationales Centrum für Tumorerkrankungen (NCT) Heidelberg
Press and Public Relations
Im Neuenheimer Feld 460
69120 Heidelberg
Phone: +49 6221 56-5930
Fax: +49 6221 56-5350
E-mail: friederike.fellenberg@nct-heidelberg.de

Dr. Stefanie Seltmann
Deutsches Krebsforschungszentrum (DKFZ)
Press Officer and Head of Press and Public Relations
Im Neuenheimer Feld 280
69120 Heidelberg
Phone: +49 6221 42-2854
Fax: +49 6221 42-2968
E-mail: S.Seltmann@dkfz.de

Doris Rübsam-Brodkorb
Universitätsklinikum Heidelberg und Medizinische Fakultät der Universität Heidelberg
Press Officer and Head of Press and Public Relations
Im Neuenheimer Feld 672
69120 Heidelberg
Phone: +49 6221 56-5052
Fax: +49 6221 56-4544
E-mail: doris.ruebsam-brodkorb@med.uni-heidelberg.de

The National Center for Tumor Diseases (NCT) Heidelberg
The National Center for Tumor Diseases (NCT) Heidelberg is a joint institution of the German Cancer Research Center, Heidelberg University Hospital and German Cancer Aid. The NCT's goal is to link promising approaches from cancer research with patient care from diagnosis to treatment, aftercare and prevention. The interdisciplinary tumor outpatient clinic is the central element of the NCT. Here the patients benefit from an individual treatment plan prepared in a timely manner in interdisciplinary expert rounds, the so-called tumor boards. Participation in clinical studies provides access to innovative therapies. The NCT thereby acts as a pioneering platform that translates novel research results from the laboratory into clinical practice. The NCT cooperates with self-help groups and supports them in their work. Since 2015, a second site for the NCT beside Heidelberg has been under development in Dresden.

The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ)
The German Cancer Research Center (DKFZ) with its more than 3,000 employees is the largest biomedical research institute in Germany. At DKFZ, more than 1,000 scientists investigate how cancer develops, identify cancer risk factors and endeavor to find new strategies to prevent people from getting cancer. They develop novel approaches to make tumor diagnosis more precise and treatment of cancer patients more successful. The staff of the Cancer Information Service (KID) offers information about the widespread disease of cancer for patients, their families, and the general public. Jointly with Heidelberg University Hospital, DKFZ has established the National Center for Tumor Diseases (NCT) Heidelberg, where promising approaches from cancer research are translated into the clinic. In the German Consortium for Translational Cancer Research (DKTK), one of six German Centers for Health Research, DKFZ maintains translational centers at seven university partnering sites. Combining excellent university hospitals with high-profile research at a Helmholtz Center is an important contribution to improving the chances of cancer patients. DKFZ is a member of the Helmholtz Association of National Research Centers, with ninety percent of its funding coming from the German Federal Ministry of Education and Research and the remaining ten percent from the State of Baden-Württemberg.

Heidelberg University Hospital and Medical Faculty Heidelberg
Health care, research and teaching of international standing
Heidelberg University Hospital is one of the most important medical centers in Germany; Heidelberg University's Medical Faculty is one of Europe's most prestigious biomedical research facilities. Their shared objective is the development of innovative diagnostics and treatments and their prompt implementation for the benefit of the patient. The hospital and faculty employ approximately 12 600 individuals and are involved in training and qualification. Every year approximately 66 000 patients are treated as inpatients or day patients in more than 50 specialized clinical departments with about 1 900 beds, with more than 1 million patients being treated as outpatients. The Heidelberg Curriculum Medicinale (HeiCuMed) is at the forefront of medical training in Germany. At present approx. 3500 prospective physicians are studying in Heidelberg.